ANTICONVULSANT EFFECT OF STEAROYLETHANOLAMINE IN THE MODEL OF EPILETIC SEIZURE
https://doi.org/10.29235/1814-6023-2018-15-1-68-75
Abstract
The purpose of this study was to determine whether stearoylethanolamine (SEA), a signaling lipid substance with cannabimimetic effects, would be effective against pentylenetetrazole induced seizure. In the pentylenetetrazole (60 mg/kg) model of acute seizure, the effects of SEA in doses of 1 and 10 mg/kg were evaluated. The vehicle for SEA consisted of alcohol, tween 80 and saline (5:5:90, vol. % accordingly) and was proved to have no effect on the seizure onset and severity by itself. Severity of seizure was estimated by Racine’s scale. It was shown that preliminary i.p. injection of SEA in a dose of 1 mg/kg made no effect on the latency before first convulsion and overall seizures severity. Nonetheless, SEA in a dose of 10 mg/kg increased the latent period before the seizure onset by 58 % and decreased the seizure severity according to Racine’s scale by 27 %. Thus, SEA produces the antiepileptic effect, but does not completely suppress seizures. The mechanism of action of SEA remains to be defined.
Supporting agencies: This work was supported by the Belarusian Republican Foundation for Fundamental Research (Grant no. M17-070 of April 18, 2017).
About the Authors
T. B. Melik-Kasumov
Institute of Physiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Ph. D. (Biol.), Leading researcher
28, Akademicheskaya Str., 220072, Minsk
E. S. Shavalda
International Sakharov Environmental Institute of Belarusian State University
Belarus
Belarus
Student
4, Nezavisimosti Ave., 220030, Minsk
A. N. Batyan
International Sakharov Environmental Institute of Belarusian State University
Belarus
Belarus
D. Sc. (Med.), Professor, Head of the Department
4, Nezavisimosti Ave., 220030, Minsk
References
1. Dokukina T. B., Golubeva T. S., Matveichuk I. V., Mahrov M. V., Loseva V. M., Krupenkina E. V., Marchuk S. A. Study of the incidence and prevalence of epilepsy in Minsk. Epilepsiya i paroksizmal’nye sostoyaniya [Epilepsia and paroxyzmal conditions], 2014, vol. 6, no. 2, pp. 29–33 (in Russian).
2. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, vol. 20, no. 5, pp. 359–368. DOI: 10.1016/j.seizure.2011.01.003
3. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends in Pharmacological Sciences, 2002, vol. 23, no. 3, pp. 113–118. DOI: 10.1016/s0165-6147(00)01974-x
4. Löscher W., Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Research, 2002, vol. 50, no. 1–2, pp. 3–16. DOI: 10.1016/s0920-1211(02)00063-3
5. Acharya M. M., Hattiangady B., Shetty A. K. Progress in neuroprotective strategies for preventing epilepsy. Progress in Neurobiology, 2008, vol. 84, no. 4, pp. 363–404. DOI: 10.1016/j.pneurobio.2007.10.010
6. Chiurchiù V., Maccarrone M. Bioactive lipids as modulators of immunity, inflammation and emotions. Current Opinion in Pharmacology, 2016, vol. 29, pp. 54–62. DOI: 10.1016/j.coph.2016.06.005
7. Hannun Y. A., Obeid L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Reviews Molecular Cell Biology, 2008, vol. 9, no. 2, pp. 139–150. DOI: 10.1038/nrm2329
8. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 1996, vol. 384, no. 6604, pp. 83–87. DOI: 10.1038/384083a0
9. Churyukanov M. V., Churyukanov V. V. Functional organization and therapeutic potential of the endogenous cannabinoid system. Eksperimental’naya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology], 2004, vol. 67, no. 2, pp. 70–78 (in Russian).
10. Shubina L. V., Kichigina V. F. Endogenous cannabinoid system of the brain: a role in the regulation of convulsive activity. Uspekhi fiziologicheskikh nauk [Progress in Physiology], 2012, vol. 43, no. 3, pp. 21–37 (in Russian).
11. Hofmann M. E., Frazier C. J. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Experimental Neurology, 2013, vol. 244, pp. 43–50. DOI: 10.1016/j.expneurol.2011.11.047
12. Romigi A., Bari M., Placidi F., Marciani M. G., Malaponti M., Torelli F., Izzi F., Prosperetti C., Zannino S., Corte F., Chiaramonte C., Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporallobe epilepsy.Epilepsia, 2010, vol. 51, no. 5, pp. 768–772.DOI: 10.1111/j.1528-1167.2009.02334.x
13. Piomelli D. The molecular logic of endocannabinoid signaling. Nature Reviews Neuroscience, 2003, vol. 4, no. 11, pp. 873–884. DOI: 10.1038/nrn1247
14. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S. C., Cascio M. G., Gutiérrez S. O., van der Stelt M., López-Rodriguez M. L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., Lutz B. CB1 Cannabinoid receptors and on-demand defense against excitotoxicity. Science, 2003, vol. 302, no. 5642, pp. 84–88. DOI: 10.1126/science.1088208
15. Bíró T., Tóth B. I., Haskó G., Paus R., Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences, 2009, vol. 30, no. 8, pp. 411–420. DOI: 10.1016/j.tips.2009.05.004
16. Bradshaw H. B., Lee S. H., McHugh D. Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins and Other Lipid Mediators, 2009, vol. 89, no. 3–4, pp. 131–134. DOI: 10.1016/j.prostaglandins.2009.04.006
17. Solomonia R., Nozadze M., Mikautadze E., Kuchiashvili N., Kiguradze T., Abkazava D., Pkhakadze V., Mamulaishvili I., Mikeladze E., Avaliani N. Effect of oleamide on convulsions caused in rats by pentylenetetrazole. Bulletin of Experimental Biology and Medicine [Bulletin of Experimental Biology and Medicine], 2008, vol. 145, no. 2, pp. 175–187 (in Russian).
18. Sheerin A. H., Zhang X., Saucier D. M., Corcoran M. E. Selective antiepileptic effects of N-рalmitoylethanolamide, a putative endocannabinoid. Epilepsia, 2004, vol. 45, no. 10, pp. 1184–1188. DOI: 10.1111/j.0013-9580.2004.16604.x
19. Pavlyut’ T. O., Melik-Kasumov T. B., Zhavoronok I. P., Antipova O. A., Pekhtereva E. I., Novakovskaya S. A., Vasilkevich A. I., Kisel’ M. A., Molchanov A. Yu. The Effect of N-palmitoylethanolamine and N-stearoylethanolamine in liposomes on the healing of experimental skin wounds. Novosti Khirurgii [Surgery news], 2016, vol. 24, no. 5, pp. 425–435 (in Russian).
20. Molchanova A. Yu. Endocannabinoid system: physiology, pathophysiology, therapeutic potential. Minsk, Belorusskaya nauka Publ., 2015. 212 p. (in Russian).
21. Gulaya N. M., Berdyshev A. G., Chumak A. A., Kindruk N. L., Gorid’ko T. N. Cardioprotective effect of N-stearoylethanolamine in anaphylactic shock in guinea pigs. Biomeditsinskaya Khimiya [Biomedical Chemistry], 2009, vol. 55, no. 6, pp. 743–749 (in Russian).
22. Hui M. A., Gang Z. H. U. The dopamine system and alcohol dependence. Shanghai Archives of Psychiatry, 2014, vol. 26, no. 2, pp. 61–68. DOI: 10.3969/j.issn.1002-0829.2014.02.002
23. Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry and Neuroscience, 2003, vol. 28, no. 4, pp. 263–274.
24. Banach M., Piskorska B., Czuczwar S. J., Borowicz K. K. Nitric oxide, epileptic seizures, and action of antiepileptic drugs. CNS and Neurological Disorders – Drug Targets, 2011, vol. 10, no. 7, pp. 808–819. DOI: 10.2174/187152711798072347
25. Maccarrone M., Cartoni A., Parolaro D., Margonelli A., Massi P., Bari M., Battista N., Finazzi-Agrò A. Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Molecular and Cellular Neuroscience, 2002, vol. 21, no. 1, pp. 126–140. DOI: 10.1006/mcne.2002.1164
26. Puligheddu M., Pillolla G., Melis M., Lecca S., Marrosu F., De Montis M. G., Scheggi S., Carta G., Murru E., Aroni S., Muntoni A. L., Pistis M. PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. PLoS One, 2013, vol. 8, no. 5, p. e64541. DOI: 10.1371/journal.pone.0064541
27. Cullingford T. Peroxisome proliferator-activated receptor alpha and the ketogenic diet. Epilepsia, 2008, vol. 49, iss. 8, pp. 70–72. DOI: 10.1111/j.1528-1167.2008.01840.x
Review
For citations:
Melik-Kasumov T.B., Shavalda E.S., Batyan A.N. ANTICONVULSANT EFFECT OF STEAROYLETHANOLAMINE IN THE MODEL OF EPILETIC SEIZURE. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(1):68-75. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-1-68-75
Views: 667
Email this article 